secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001437749-24-034049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports Q3 net loss $1.3M; in-licensed Wilson disease drug ALXN-1840; raised $17.7M
--------------------------------------------------------------------------------

- Net loss Q3 2024 $1.3M ($0.37/share) vs $2.0M ($0.69/share) Q3 2023.
- Exclusive license from Alexion for ALXN-1840 (Wilson disease, Phase 3 completed); planning FDA discussions.
- MNPR-101-Lu Phase 1a therapy trial active and enrolling in Australia; MNPR-101-Zr imaging trial shows tumor uptake.
- Completed public offering Oct 30, 2024: 1,181,540 shares at $16.25/sh, net $17.7M.
- Cash $6.0M at Sept 30; pro forma runway into first half 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924034049/0001437749-24-034049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924034049/mnpr20241107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer